The Application of Mitochondria-Targeted Peptide SS-31 in Anti-Aging

I. Mitochondria and Aging: A NUPEPS Scientific Perspective

Mitochondria—often described as the cell’s powerhouse—generate most of the cell’s ATP and participate in essential metabolic and signaling pathways. With age, mitochondrial performance naturally declines, contributing significantly to the aging process. This decline includes:

• Accumulation of mitochondrial DNA (mtDNA) mutations
• Decreased activity of mitochondrial respiratory chain complexes, reducing ATP output
• Increased mitochondrial reactive oxygen species (ROS), which damage proteins, lipids, and nucleic acids
• Disturbed calcium homeostasis, impairing normal cellular function

These age-related changes create a feedback loop of energy loss, oxidative damage, and cellular dysfunction—ultimately accelerating biological aging.

II. Mechanisms of Action of SS-31 (Elamipretide)

1. Enhancing Mitochondrial Energy Metabolism

Improved ADP Sensitivity

Aging reduces mitochondrial responsiveness to ADP, compromising ATP production. Research shows that SS-31 interacts directly with the mitochondrial ADP/ATP carrier ANT, increasing ADP uptake and improving mitochondrial respiration. In aging muscle tissue, this leads to:

• Higher ADP-stimulated respiration
• Increased ATP generation
• Improved mitochondrial energetic efficiency

Support of Respiratory Chain Complexes

SS-31 may stabilize the structure of respiratory chain complexes or modulate proteins that affect their function. Studies demonstrate restored complex activity in aging models following SS-31 treatment, highlighting its beneficial impact on mitochondrial bioenergetics.

2. Reducing Oxidative Stress

Lowering Mitochondrial ROS Production

SS-31 reduces mitochondrial ROS through:

• Improved electron transport efficiency, minimizing electron leakage
• Direct interaction with mitochondrial membranes, decreasing oxidative damage sites

In aged cardiac cells, SS-31 significantly lowers mitochondrial ROS, demonstrating strong antioxidant potential.

Reinforcing Antioxidant Defenses

SS-31 may support endogenous antioxidant systems, such as:

• Superoxide dismutase (SOD)
• Catalase (CAT)
• Glutathione peroxidase (GSH-Px)

In cellular models, SS-31 increases the activity of these enzymes, improving cellular resilience against oxidative stress.

3. Stabilizing Mitochondrial Membranes

Selective Binding to Mitochondrial Phospholipids

SS-31 has a chemical structure that enables high affinity for phosphatidylserine-rich regions of the mitochondrial membrane. This interaction:

• Protects membrane phospholipids from oxidation
• Helps maintain membrane potential
• Prevents opening of the mitochondrial permeability transition pore (mPTP)

Regulation of Membrane-Associated Proteins

SS-31 may also influence key mitochondrial membrane proteins such as VDAC, supporting healthy metabolite transport and signaling.

III. Anti-Aging Effects of SS-31 Across Systems

1. Cardiovascular System

Improved Cardiac Function in Aging

In aged mouse models, 8 weeks of SS-31 treatment led to:

• Enhanced diastolic function
• Reduced mitochondrial proton leak
• Decreased cardiac ROS and protein oxidation
• Restoration of redox balance
• Increased phosphorylation of cMyBP-C Ser282, supporting improved cardiac relaxation

Vascular Protection

In hypertension-induced cerebral microbleed models, SS-31:

• Reduced mitochondrial ROS in vascular tissue
• Mitigated oxidative damage
• Delayed onset and reduced incidence of microbleeds

This underscores SS-31’s potential to support vascular integrity with age.

2. Nervous System

Protection Against Cognitive Decline

In aged mice exposed to isoflurane, SS-31:

• Reversed mitochondrial dysfunction
• Restored synaptic plasticity proteins (synaptophysin, PSD-95, p-CREB)
• Enhanced BDNF signaling
• Upregulated NMDA receptor subunits (NR2A, NR2B) and CaMKII isoforms

These effects collectively improved learning and memory.

Mitigating Effects of Sleep Deprivation

Short-term SS-31 treatment in aged mice prevented sleep-deprivation-induced:

• Cognitive impairment
• ROS elevation
• Mitochondrial ATP loss
• Neuroinflammation

SS-31 also normalized synaptic plasticity markers, demonstrating strong neuroprotective properties.

3. Renal System

In 26-month-old mice, 8 weeks of SS-31 treatment:

• Improved mitochondrial morphology
• Reduced glomerulosclerosis
• Lowered cellular aging markers (p16, SA-β-Gal)
• Enhanced epithelial and endothelial cell density
• Decreased indicators of podocyte injury

These findings support SS-31’s ability to restore kidney structure and mitochondrial health in aged organisms.

4. Cellular-Level Effects

Delaying Cellular Senescence

In HEK293T cells under oxidative stress, SS-31:

• Reduced SA-β-gal staining
• Lowered ROS
• Improved mitochondrial membrane potential
• Increased ATP
• Downregulated aging-related proteins (p53, p21, Ac-p53)
• Upregulated Sirt1

These results demonstrate SS-31’s capacity to counteract cellular aging pathways.

Protection Against Oxidative Damage

In ARPE-19 cells, SS-31 treatment:

• Improved cell survival
• Reduced ROS
• Preserved mitochondrial membrane potential
• Lowered cell death markers
• Suppressed RIP3 upregulation

This highlights potent cytoprotective effects relevant to aging-associated tissue damage.

Conclusion

At NUPEPS Peptides, we recognize SS-31 (Elamipretide) as a promising peptide-based strategy for supporting mitochondrial health and combating age-related decline. Through its multifaceted influence on energy metabolism, oxidative stress reduction, and structural maintenance of mitochondria, SS-31 demonstrates significant potential across cardiovascular, neurological, renal, and cellular aging models.